Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is expected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Taysha Gene Therapies to post earnings of ($0.11) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Taysha Gene Therapies Stock Up 0.7%

Shares of NASDAQ:TSHA opened at $4.58 on Wednesday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.88 and a beta of 1.01. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $6.02. The business has a 50-day moving average price of $5.07 and a 200 day moving average price of $4.29. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Analysts Set New Price Targets

Several equities analysts have recently commented on TSHA shares. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Friday, November 14th. Raymond James Financial restated a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Citizens Jmp set a $8.00 price objective on Taysha Gene Therapies in a research note on Wednesday, November 5th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Wells Fargo & Company boosted their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

Insider Transactions at Taysha Gene Therapies

In related news, CFO Kamran Alam sold 23,849 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at $6,655,853.46. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the sale, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at approximately $13,407,064.77. This trade represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 968,795 shares of company stock valued at $4,518,093. Corporate insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. purchased a new stake in Taysha Gene Therapies in the second quarter valued at approximately $11,178,000. Barclays PLC boosted its stake in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after purchasing an additional 4,697,611 shares during the period. State Street Corp grew its position in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Taysha Gene Therapies in the second quarter valued at $6,823,000. Finally, Vestal Point Capital LP raised its holdings in shares of Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.